As reported by the user facility: customer reports that chemical phlebitis is occurring.This is occurring with medications such as taxotere, taxol, cistplatin, adromycin.Customer verbalizes that this has been occurring for the past couple of months, and when they use nexiva brand, this does not occur.
|
(b)(4).The samples and all available information were forwarded to the manufacturer for further evaluation.Their report states that they received 2 introcan safety 3-w pur 22g 0.9x25mm-us in original packaging.Lot number printed on the returned packages were 15e18g8371 and material# 4251128-02.Visually inspected the returned samples and found no abnormalities.Cytotoxicity test requires a minimum of 50 pcs of samples, hence, no test can be performed on the two samples returned.The test conducted during the development of introcan safety 3 shows that the product complies with (b)(4).Device history record (dhr): reviewed the device history record and there were no defect encountered during in-process or final control inspection.Process cards also show no abnormalities.Sterility test information: process sterilization process sterilization reviewed and found no discrepancy or deviation.All parameter are within specification.Bi sterility: bi sterility result reviewed and found all results are within the specification.Based on the results of this investigation, no specific conclusions can be made regarding the cause of the event.If additional pertinent information becomes available, a follow up report will be submitted.
|